Baloxavir to treat acute fluDecember 13, 2018
The US FDA has granted approval to baloxavir marboxil for the treatment of acute uncomplicated influenza.
The oral antiviral drug has been approved for all patients 12 years of age and older who have been symptomatic for no more than 48 hours.
The safety and efficacy of baloxavir were demonstrated in two randomized controlled clinical trials of 1,832 patients where participants were assigned to receive either baloxavir, a placebo, or another antiviral flu treatment within 48 hours of experiencing flu symptoms. In both trials, patients treated with baloxavir had a shorter time to alleviation of symptoms compared with patients who took the placebo.